Nor is it clear what effect such a step might have on the campaign to vanquish the outbreak.
Activists and humanitarian institutions cheered after the U.S. reversed course Wednesday and called for a waiver of intellectual property protections on the vaccine. The decision ultimately is up to the 164-member World Trade Organization, and if just one country votes against a release, the proposal will fail.
The Biden administration announcement made the U.S. the first country in the developed world with big vaccine manufacturing to publicly support the waiver idea floated by India and South Africa in October. On Thursday, French President Emmanuel Macron embraced it as well.
I ultimately favor this opening up of the intellectual property,” Macron said at a vaccine center.
However, like many pharmaceutical companies, Macron insisted that a waiver would not solve the problem of access to vaccines. He said manufacturers in places like Africa are not now equipped to make COVID-19 vaccines, so donations of shots from wealthier countries should be given priority instead. Pfizer, Moderna, Johnson & Johnson, and AstraZeneca — all companies with licensed COVID-19 vaccines — had no immediate comment. However, Moderna has long said it will not pursue rivals for patent infringement during the pandemic.
“On the current trajectory, if we don’t do more, if the entire world doesn’t do more, the world won’t be vaccinated until 2024,” he said in an interview with NBC while visiting Ukraine. India, as expected, welcomed the move. Australian Prime Minister Scott Morrison called the U.S. position “great news.”
Italian Foreign Minister Luigi Di Maio wrote on Facebook that the U.S. announcement was “a significant signal” and that the world needs “free access” to vaccine patents. But Italian Premier Mario Draghi was more circumspect. Russian President Vladimir Putin said his country would support it. U.N. Secretary-General Antonio Guterres welcomed the U.S. decision too.